Similarly, PD‐1/PD‐L1 inhibitor combined with anti‐angiogenesis (such as axitinib, cabozantinib, lenvatinib, and bevacizumab) has been FDA‐approved for kidney cancer, endometrial cancer, and hepatocellular carcinoma [33]. This evidence concerns the gene PDCD1 and kidney cancer.